A Phase 4 interventional study of No aspirin (Prasugurel monotherapy) and 12-month DAPT in ST-segment Elevation Myocardial Infarction (STEMI), sponsored by Kindai University. Completed at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Kindai University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in ST Elevation Myocardial Infarction with a site in Japan — 1 open to participants now, 2 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Japan.
Among the 10 studies in ST Elevation Myocardial Infarction with a site in Japan, this one is the only one that started in 2023, is one of 2 in phase 4, and was the 9th registered.
855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →1 of the 10 studies in ST Elevation Myocardial Infarction with a site in Japan is open now. Recruiting first, the newest first:
Tokai University · Sites in Japan
Ages 21+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,268 is above the median of 194 across 531 interventional studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 353 across the 8 interventional studies, 749 across the 2 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 9 most frequent:
Kindai University is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Kindai University has 1 study filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
1 of the studies in ST Elevation Myocardial Infarction with a site in Japan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in ST Elevation Myocardial Infarction with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).
In the STOPDAPT-2 ACS trial (NCT03462498), ischemic events (especially myocardial infarction) was significantly increased with 1-month DAPT followed by clopidogrel monotherapy, as compared to 12-month DAPT in patients with acute coronary syndrome (ACS). This was potentially attributable to clopidogrel, instead of prasugrel, which is more potent and has less individual difference in efficacy. On the other hand, previous studies including the STOPDAPT-2 ACS that evaluated the safety and efficacy of monotherapy with a P2Y12 inhibitor without aspirin consistently and significantly reduced the risk of bleeding, compared with standard DAPT. Consequently, there has been growing necessity to establish the safety with P2Y12 inhibitor monotherapy in terms of major adverse cardiovascular events. Therefore, we have planned to evaluate the non-inferiority of P2Y12 inhibitor monotherapy with prasugrel versus standard 12-month DAPT with prasugrel and aspirin in terms of the incidence of major cardiovascular events at 12 months after primary PCI in patients with STEMI using Platinum-Chromium Everolimus Eluting Stent (PtCr-EES; SYNERGYTM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To start prasugrel monotherapy before primary percutaneous coronary intervention (PCI).
Drug: No aspirin (Prasugurel monotherapy)
To start dual antiplatelet therapy with prasugrel and aspirin for 12 months before primary percutaneous coronary intervention (PCI).
Drug: 12-month DAPT
12-month prasugrel monotherapy
Also known as: Experimental arm
12-month dual antiplatelet therapy with prasugrel and aspirin
Also known as: Reference arm
Major adverse cardiovascular events
Composite of all-cause death, myocardial infarction, or stroke
Time frame: 12 months
Major secondary bleeding endpoint: Type 3 or 5 bleeding in Bleeding Academic Research Consortium (BARC) criteria
Type 3 or 5 bleeding defined by BARC criteria
Time frame: 12 months
All-cause death
Death from any cause
Time frame: 12 months
Cardiovascular death
Death from cardiovascular cause
Time frame: 12 months
Non-cardiovascular death
Death from non-cardiovascular cause
Time frame: 12 months
Myocardial infarction (Periprocedual/ Spontaneous)
Defined by the Academic Research Consortium (ARC)-2
Time frame: 12 months
Stroke (Ischemic/ Haemorrhagic)
Including both ischemic and haemorrhagic stroke
Time frame: 12 months
Ischemic stroke
Ischemic stroke with symptom lasting over 24 hours
Time frame: 12 months
Hemorrhagic stroke
Intracerebral hemorrhage or subarachnoidal hemorrhage not associated with trauma
Time frame: 12 months
Stent thrombosis
Stent thrombosis defined by Academic Research Consortium (ARC)-2 definition
Time frame: 12 months
Target lesion failure
Cardiovascular death, target vessel myocardial infarction, clinically indicated target lesion revascularization
Time frame: 12 months
Target vessel failure
Cardiovascular death, target vessel myocardial infarction, clinically indicated target vessel revascularization
Time frame: 12 months
Patient-Oriented Composite Endpoint
All-cause death, stroke, myocardial infarction, and all revascularization, defined by the Academic Research Consortium (ARC)-2
Time frame: 12 months
Any target lesion revascularization
Revascularization to the target lesions (including 5mm of both ends of the stent\[s\]) regardless of PCI or CABG
Time frame: 12 months
Clinically-driven target lesion revascularization
Target lesion revascularization with the anginal symptoms or the positive test for ischemia
Time frame: 12 months
Non-target lesion revascularization
Revascularization to non-target lesions regardless PCI or CABG
Time frame: 12 months
Coronary artery bypass grafting
Any coronary artery bypass grafting
Time frame: 12 months
Any target vessel revascularization
Revascularization to the target vessel
Time frame: 12 months
Any coronary revascularization
Revascularization regardless of PCI or CABG
Time frame: 12 months
Type 2 bleeding in Bleeding Academic Research Consortium (BARC) criteria
Type 2 bleeding defined by BARC criteria
Time frame: 12 months
Type 3 bleeding in Bleeding Academic Research Consortium (BARC) criteria
Type 3 bleeding defined by BARC criteria
Time frame: 12 months
Type 4 bleeding in Bleeding Academic Research Consortium (BARC) criteria
Type 4 bleeding defined by BARC criteria
Time frame: 12 months
Type 5 bleeding in Bleeding Academic Research Consortium (BARC) criteria
Type 5 bleeding defined by BARC criteria
Time frame: 12 months
Type 2, 3, or 5 bleeding in Bleeding Academic Research Consortium (BARC) criteria
Type 2, 3, or 5 bleeding defined by BARC criteria
Time frame: 12 months
Major bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria
Major bleeding defined by TIMI criteria
Time frame: 12 months
Minor bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria
Minor bleeding defined by TIMI criteria
Time frame: 12 months
Major or minor bleeding in Thrombolysis in Myocardial Infarction (TIMI) criteria
Major or minor defined by TIMI criteria
Time frame: 12 months
Severe bleeding in Global utilization of streptokinase and tPA for occluded arteries (GUSTO) criteria
Severe bleeding defined by GUSTO criteria
Time frame: 12 months
Moderate bleeding in Global utilization of streptokinase and tPA for occluded arteries (GUSTO) criteria
Moderate bleeding defined by GUSTO criteria
Time frame: 12 months
Moderate or severe bleeding in Global utilization of streptokinase and tPA for occluded arteries (GUSTO) criteria
Moderate or severe bleeding defined by GUSTO criteria
Time frame: 12 months
Intracranial bleeding
Intracranial bleeding regardless of spontaneous or trauma
Time frame: 12 months
Gastrointestinal bleeding
Bleeding from gastrointestinal tract regardless of severity
Time frame: 12 months
Gastrointestinal complaints
Requirement of upper gastric fiberscopy to examine the gastrointestinal complaints
Time frame: 12 months
Plan to share: No
Ran from Apr 2023 to primary completion in Feb 2026, 34 months.
Of 44 non-industry phase 4 interventional studies under ST Elevation Myocardial Infarction, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 74. This study's 34 months is close to that.
Counting every sponsor, half of 49 studies reached it within 34 months; a quarter within 22 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Feb 2023 → Apr 2023, primary completion Jan 2025 → Feb 2026 and completion Jan 2028 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl ester
ST Elevation Myocardial Infarction →
Kindai University